WO2000042183A3 - Marqueur tumoral zsig62 - Google Patents

Marqueur tumoral zsig62 Download PDF

Info

Publication number
WO2000042183A3
WO2000042183A3 PCT/US2000/001902 US0001902W WO0042183A3 WO 2000042183 A3 WO2000042183 A3 WO 2000042183A3 US 0001902 W US0001902 W US 0001902W WO 0042183 A3 WO0042183 A3 WO 0042183A3
Authority
WO
WIPO (PCT)
Prior art keywords
zsig62
tumor suppressor
gene
mutations
suppressor genes
Prior art date
Application number
PCT/US2000/001902
Other languages
English (en)
Other versions
WO2000042183A2 (fr
Inventor
Paul O Sheppard
Julia E Novak
Fenella C Raymond
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Priority to CA002371752A priority Critical patent/CA2371752A1/fr
Priority to AU33507/00A priority patent/AU3350700A/en
Publication of WO2000042183A2 publication Critical patent/WO2000042183A2/fr
Publication of WO2000042183A3 publication Critical patent/WO2000042183A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Des études ont démontré que les mutations de gènes suppresseurs de tumeurs se produisent à un stade précoce du processus de carcinogenèse, et que ces mutations sont corrélées à un développement ultérieur du cancer. La détection de telles modifications devrait permettre de disposer de marqueurs moléculaires utiles au diagnostic, à la surveillance, à l'identification et à l'intervention à un stade précoce et à l'établissement d'un pronostic. Un nouveau gène humain, dénommé 'Zsig62', est localisé dans une région du chromosome 16q qui est associée au cancer du sein et de la prostate, et qui semble contenir des gènes suppresseurs de tumeurs. De même qu'un gène suppresseur de tumeur, le gène Zsig62 est exprimé dans des tissus normaux particuliers mais pas dans les tumeurs dérivées de ces tissus.
PCT/US2000/001902 1999-01-19 2000-01-18 Marqueur tumoral zsig62 WO2000042183A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CA002371752A CA2371752A1 (fr) 1999-01-19 2000-01-18 Marqueur tumoral zsig62
AU33507/00A AU3350700A (en) 1999-01-19 2000-01-18 Tumor marker zsig62

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23361099A 1999-01-19 1999-01-19
US09/233,610 1999-01-19

Publications (2)

Publication Number Publication Date
WO2000042183A2 WO2000042183A2 (fr) 2000-07-20
WO2000042183A3 true WO2000042183A3 (fr) 2003-05-08

Family

ID=22877973

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/001902 WO2000042183A2 (fr) 1999-01-19 2000-01-18 Marqueur tumoral zsig62

Country Status (3)

Country Link
AU (1) AU3350700A (fr)
CA (1) CA2371752A1 (fr)
WO (1) WO2000042183A2 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992021754A1 (fr) * 1991-06-07 1992-12-10 Osaka Bioscience Institute Adn qui code pour le recepteur de la secretine et polypeptide pour lequel code cet adn
WO1999053095A2 (fr) * 1998-04-09 1999-10-21 Whitehead Institute For Biomedical Research Marqueurs bialleliques
WO2000037677A1 (fr) * 1998-12-22 2000-06-29 Imperial Cancer Research Technology Limited Cancer en rapport avec un gene suppresseur de tumeur du chromosome humain 16q

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992021754A1 (fr) * 1991-06-07 1992-12-10 Osaka Bioscience Institute Adn qui code pour le recepteur de la secretine et polypeptide pour lequel code cet adn
WO1999053095A2 (fr) * 1998-04-09 1999-10-21 Whitehead Institute For Biomedical Research Marqueurs bialleliques
WO2000037677A1 (fr) * 1998-12-22 2000-06-29 Imperial Cancer Research Technology Limited Cancer en rapport avec un gene suppresseur de tumeur du chromosome humain 16q

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
CHEN T ET AL: "Deletion map of chromosome 16q in ductal carcinoma in situ of the breast: refining a putative tumor suppressor gene region", CANCER RESEARCH, vol. 56, 1996, pages 5605 - 5609, XP002136829 *
DATABASE EMBL NUCLEOTIDE AND PROTEIN SEQUENCES, 15 July 1999 (1999-07-15), HINXTON, GB, XP002147258 *
DATABASE WPI Section Ch Week 199252, Derwent World Patents Index; Class B04, AN 1992-433652, XP002147259 *
ELO J P ET AL: "Three independently deleted regions at chromosome arm 16q in human prostate cancer: Allelic loss at 16q24.1-q24.2 is associated with aggressive behaviour of the disease, recurrent growth, poor differentiation of the tumour and poor prognosis for the patient.", BRITISH JOURNAL OF CANCER, vol. 79, no. 1, January 1999 (1999-01-01), pages 156 - 160, XP000925910, ISSN: 0007-0920 *
ELO JUSSI P ET AL: "Loss of heterozygosity at 16q24.1-q24.2 is significantly associated with metastatic and aggressive behavior of prostate cancer.", CANCER RESEARCH, vol. 57, no. 16, 1997, pages 3356 - 3359, XP000925961, ISSN: 0008-5472 *
KAWAKAMI MASAKO ET AL: "Involvement of H-cadherin (CDH13) on 16q in the region of frequent deletion in ovarian cancer.", INTERNATIONAL JOURNAL OF ONCOLOGY, vol. 15, no. 4, October 1999 (1999-10-01), pages 715 - 720, XP000925920, ISSN: 1019-6439 *
LATIL A ET AL: "Loss of heterozygosity at chromosome 16q in prostate adenocarcinoma:identification of thre independent regions", CANCER RESEARCH, vol. 57, 15 March 1997 (1997-03-15), pages 1058 - 1062, XP002136828 *
SCHMUTZLER R K ET AL: "ASSOCIATION OF ALLELIC LOSSES ON HUMAN CHROMOSOMAL ARMS 11Q AND 16Q IN SPORADIC BREAST CANCER", INTERNATIONAL JOURNAL OF CANCER,US,NEW YORK, NY, vol. 69, no. 4, 22 August 1996 (1996-08-22), pages 307 - 311, XP000791171, ISSN: 0020-7136 *
WHITMORE SCOTT A ET AL: "Construction of a high-resolution physical and transcription map of chromosome 16q24.3: A region of frequent loss of heterozygosity in sporadic breast cancer.", GENOMICS, vol. 50, no. 1, 15 May 1998 (1998-05-15), pages 1 - 8, XP000925915, ISSN: 0888-7543 *

Also Published As

Publication number Publication date
CA2371752A1 (fr) 2000-07-20
AU3350700A (en) 2000-08-01
WO2000042183A2 (fr) 2000-07-20

Similar Documents

Publication Publication Date Title
Cooney et al. Distinct regions of allelic loss on 13q in prostate cancer
Forus et al. Molecular characterization of a novel amplicon at 1q21-q22 frequently observed in human sarcomas
EP1522594A3 (fr) Methode et trousses pour evaluer un cancer
AU2001287639A1 (en) Trp8, trp9 and trp10, markers for cancer
WO2002092854A3 (fr) Genes exprimes dans le cancer du sein en tant que cibles therapeutique et de pronostic
WO2002044331A3 (fr) Dap-kinase et hoxa9, deux genes humains associes a la genese, a la progression et a l'agressivite du cancer du poumon non a petites cellules
WO1999014327A3 (fr) Genes amplifies dans des tumeurs, anticorps diriges contre les proteines codees par ces genes, et leur utilisation dans le diagnostic et le traitement du cancer
WO2007006408A3 (fr) Methodes et kits de prevision et de surveillance d'une reponse directe a une therapie anti-cancereuse
Choy et al. Impaired expression and promotor hypermethylation of O6-methylguanine-DNA methyltransferase in retinoblastoma tissues
WO2005119260A3 (fr) Methodes de prediction et de surveillance de reponse au traitement du cancer
WO2003065006A3 (fr) Procedes et compositions pour le traitement du cancer utilisant les molecules 140, 1470, 1686, 2089, 2427, 3702, 5891, 6428, 7181, 7660, 25641, 69583, 49863, 8897, 1682, 17667, 9235, 3703, 14171, 10359, 1660, 1450, 18894, 2088, 32427, 2160, 9252, 9389, 1642, 85269, 10297, 1584, 9525, 14124, 4469, 8990, 2100, 9288, 64698, 10
WO2000055629A3 (fr) Nouvelles techniques permettant de traiter et de diagnostiquer le cancer du sein, compositions et techniques de criblage pour modulateurs de cancer du sein
WO2003032813A3 (fr) Methodes de traitement du carcinome
WO2001009189A3 (fr) Compositions et procedes de traitement de tumeurs
WO2002012285A3 (fr) Suppresseur de tumeur car-1
AU2001290949A1 (en) Id-1 and id-2 genes and products as diagnostic and prognostic markers and therapeutic targets for treatment of breast cancer and other types of carcinoma
Qin Chromosomal aberrations related to metastasis of human solid tumors
WO2000015666A3 (fr) Compositions et methodes de traitement des tumeurs
WO2004075835A3 (fr) Procédés de traitement de carcinome
EP1907842A4 (fr) Identification des tumeurs du cancer bronchopulmonaire 'non à petites cellules'' (nsclc) exprimant pdgfr-alpha
WO2000042183A3 (fr) Marqueur tumoral zsig62
WO2003070889A3 (fr) Genes specifiques de la prostate et leur utilisation dans la conception ou la therapie
CA2435320A1 (fr) Compositions et methodes destinees a l'utilisation de fragments de fibronectine dans le diagnostic du cancer
WO2003018770A3 (fr) Oncogenes amplifies et leur implication dans le cancer
Louhelainen et al. Initiation-development modelling of allelic losses on chromosome 9 in multifocal bladder cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2371752

Country of ref document: CA

Ref country code: CA

Ref document number: 2371752

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/007331

Country of ref document: MX

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase